List of Rybelsus drug patents

Rybelsus is owned by Novo.

Rybelsus contains Semaglutide.

Rybelsus has a total of 8 drug patents out of which 0 drug patents have expired.

Rybelsus was authorised for market use on 20 September, 2019.

Rybelsus is available in tablet;oral dosage forms.

Rybelsus can be used as method of treating type 2 diabetes mellitus.

The generics of Rybelsus are possible to be released after 02 May, 2034.

RYBELSUS's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(2 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US11382957 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
Dec, 2031

(8 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(9 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M (M) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage

RYBELSUS family patents

21

United States

18

European Union

8

Japan

7

Korea, Republic of

7

China

6

Denmark

6

Mexico

6

Hungary

6

Portugal

6

Spain

6

Poland

5

Australia

5

Brazil

4

South Africa

4

Slovenia

4

Russia

4

Croatia

4

RS

4

Canada

3

Israel

3

Lithuania

3

Cyprus

2

Norway

2

Malaysia

2

Taiwan, Province of China

1

Austria

1

Saudi Arabia

1

Germany

1

Netherlands

1

Ukraine

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in